Contributors:Schnippel, K, Ndjeka, N, Maartens, G, Meintjes, G, Master, I, Ismail, N, Hughes, J, Ferreira, H, Padanilam, X, Romero, R, Te Riele, J, Conradie, F
Addition of bedaquiline to treatment for multidrug-resistant tuberculosis was associated with an increased risk of death in a phase 2b clinical trial, resulting in caution from WHO. Following a compassionate access programme and local regulatory approval, the South African National Tuberculosis Programme began widespread use of bedaquiline in March, 2015, especially among patients with extensively drug resistant tuberculosis for whom no other effective treatment options were available. We aimed to compare mortality in patients on standard regimens with that of patients on regimens including bedaquiline.
Many health programs can assess coverage using standardized cluster survey methods, but estimating the coverage of nutrition programs presents a special challenge due to low disease prevalence. Used since 2012, the Semi-Quantitative Evaluation of Access and Coverage (SQUEAC) employs both qualitative and quantitative methods to identify key barriers to access and estimate coverage of therapeutic feeding programs. While the tool has been increasingly used in programs, the validity of certain methodological elements has been the subject of debate.
Contributors:Ferreyra, C, O’Brien, D, Alonso, B, Al-Zomour, A, Ford, N
Contributors:Hewison, C, Bastard, M, Khachatryan, N, Kotrikadze, T, Hayrapetyan, A, Avaliani, Z, Kiria, N, Yegiazaryan, L, Chumburidze, N, Kirakosyan, O, Atshemyan, H, Qayyum, S, Lachenal, N, Varaine, F, Huerga, H
Bedaquiline (BDQ) was initially only available through compassionate use programmes.